Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children.

Pharmacogenetics and genomics - 1 Jan 2018

Allegra Sarah, Cusato Jessica, De Francia Silvia, Longo Filomena, Pirro Elisa, Massano Davide, Piga Antonio, D'Avolio Antonio

Abstract excerpt

OBJECTIVES: Patients with β-thalassemia major have extremely low vitamin D levels, owing to reduced intestinal absorption, subicteric tint, and/or iron-induced higher pigmentation. We investigated whether some polymorphisms within the VDR, CYP24A1, CYP27B1, and GC genes could play a role in deferasirox pharmacokinetics in a cohort of pediatric patients. PATIENTS AND METHODS: Eighteen children with β-thalassemia...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 25-Hydroxyvitamin D3 1-alpha-Hydroxylase
Share to Benzoates

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to beta-Thalassemia

Share to Pharmacogenomic Variants

Share to Receptors, Calcitriol

Share to Triazoles

Share to Vitamin D

Share to Vitamin D3 24-Hydroxylase

Source

Identifiers

PMID: 29099735
DOI: 10.1097/FPC.0000000000000315

Genes

VDR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children.PMID 29099735Read ↗

Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.Semantic proximity Read ↗

Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Semantic proximity Read ↗

Role of pharmacogenetics on deferasirox AUC and efficacy.Semantic proximity Read ↗

Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Semantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients.Semantic proximity Read ↗

Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?Semantic proximity Read ↗

Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction.Semantic proximity Read ↗

Genetic Polymorphisms in Cytochrome P450 Enzymes Involved in Vitamin D Metabolism and the Vitamin D Receptor: Their Clinical RelevanceSemantic proximity Read ↗

Fok-I gene polymorphism of vitamin D receptor in patients with beta-thalassemia major and its effect on vitamin D status.Semantic proximity Read ↗

Vitamin D pathway gene polymorphisms affecting daclatasvir plasma concentration at 2 weeks and 1 month of therapy.Semantic proximity Read ↗

Vitamin D binding protein gene polymorphism as a risk factor for vitamin D deficiency in Thais.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.